Amgen Launches Amgevita (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada
Shots:
- The company reports the availability of Amgevita- referencing Humira to treat 11 chronic inflammatory conditions in Canada
- Amgevita is available as a prefilled syringe and a prefilled pen (SureClick autoinjector) with a broad range of pack sizes to support dosing for each indication and available in a citrate-free formulation. Amgevita is reimbursed on the public drug for all indications of Humira in British Columbia- Alberta- Ontario- Quebec- New Brunswick and Newfoundland
- The approval was based on the clinical study that supports bio-similarity with the Humira and showed no clinical differences from the reference product
Ref: Amgen | Image: Amgen
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com